China SXT Pharmaceuticals annual revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals reported $1.1M in revenue for fiscal 2026, a decrease of 34.63% from the previous fiscal year.
View full China SXT Pharmaceuticals company overview| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.1M | −$602,855 | −34.63% |
| 2025 | 2025-03-31 | $1.7M | −$187,590 | −9.73% |
| 2024 | 2024-03-31 | $1.9M | −$43,182 | −2.19% |
| 2023 | 2023-03-31 | $2.0M | −$630,602 | −24.23% |
| 2022 | 2022-03-31 | $2.6M | −$2.2M | −45.53% |
| 2021 | 2021-03-31 | $4.8M | −$384,695 | −7.45% |
| 2020 | 2020-03-31 | $5.2M | −$1.8M | −26.38% |
| 2019 | 2019-03-31 | $7.0M | −$7,217 | −0.10% |
| 2018 | 2018-03-31 | $7.0M | $2.1M | +43.79% |
| 2017 | 2017-03-31 | $4.9M | — | — |
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
TickerStat standardizes reported company facts from SEC EDGAR. Derived growth rates use the displayed revenue values and are not company guidance or forecasts.
Review China SXT Pharmaceuticals filings at SEC.gov ↗